Funding & Investments

VectorY adds €74.5m, with EIB and Eli Lilly backing, to carry its ALS gene therapy to a final trial readout

The Amsterdam biotech brings in Angelini Ventures, Invest-NL and the EIB as new backers, three years after its €129m Series A, to fund the PIONEER-ALS study of VTx-002 and a Huntington's programme.

Author
Jascinta Clark
Published
Reading time
3 min read
Views
Loading views
VectorY Therapeutics cover image

VectorY Therapeutics, the Amsterdam company that uses gene therapy to turn neurons into antibody factories, has raised €74.5m ($83.5m) in fresh financing. The money is meant to take its lead ALS candidate, VTx-002, all the way to the final readout of its first clinical study, which puts the company's main bet in front of investors within the life of this round.

The round, announced on 11 November, brings in three new names: Angelini Ventures, the venture arm of the Italian Angelini group, the Dutch state-backed investor Invest-NL, and the European Investment Bank. The EIB said its share is a €30m convertible loan supported by the European Commission's InvestEU programme. At least one trade report describes the package as an extension of the company's Series A rather than a new lettered round.

Most of the existing shareholder base came back. Forbion took part through both its growth and venture funds, alongside EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures, Eli Lilly and the ALS Investment Fund.

A smaller cheque than in 2023, with public money in the mix

VectorY last raised in November 2023, when EQT Life Sciences and Forbion co-led a €129m Series A, one of the larger private biotech rounds in Europe that year. The new money is a little over half that size. The mix has also changed: a sizeable part now comes from public or policy-driven lenders, with the EIB loan alone covering about 40% of the total and Invest-NL joining the cap table.

For European biotech founders, the structure is worth a look. InvestEU-backed loans from the EIB give clinical-stage companies a way to add capital alongside their venture investors. A convertible loan lets the company draw on the capital now without setting a fresh valuation for that slice, though the terms of the conversion were not disclosed.

Jim Scibetta, who took over as chief executive in December 2024, said the round shows "strong confidence in our team, our platform and the potential of our pipeline". Wouter Joustra, a general partner at Forbion, said the money would help VectorY move its current work forward "while developing additional programs".

Where the €74.5m goes

The first call on the cash is PIONEER-ALS, the Phase 1/2 study of VTx-002. The trial dosed its first participant in February 2026 and in September the company said it would grow from 12 to 36 people. It is an open-label, dose-escalation study testing two dose levels in adults with ALS at sites in the US, Europe and the UK.

Its main job is to show the therapy is safe and tolerable and to measure how it behaves in the body. The company will also track neurofilament light chain, a blood marker of nerve damage, along with TDP-43 pathway biomarkers, the standard ALS functional rating scale, breathing capacity, grip strength and survival. VectorY has not given a date for the final readout.

VTx-002 targets TDP-43, a protein that clumps inside nerve cells in up to 97% of people with ALS, according to the company. Instead of infusing an antibody again and again, VectorY packages the genetic instructions for one into an AAV viral vector, so that neurons make the antibody themselves. The idea is a single treatment that keeps working inside the brain and spinal cord, where conventional antibodies struggle to reach in useful amounts.

The rest of the money supports the earlier pipeline:

  • VTx-003, aimed at the mutant huntingtin protein in Huntington's disease
  • VTx-004, a TDP-43 programme for frontotemporal dementia
  • VTx-005, directed at phosphorylated tau in Alzheimer's disease

Only VTx-003 is named as a direct beneficiary of this round. No trial timing has been given for any of the three.

A gene therapy veteran's third company

VectorY's scientific roots trace back to co-founder Sander van Deventer, now president of research and development. He previously co-founded Amsterdam Molecular Therapeutics, which became uniQure, and the life sciences investor Forbion, and he worked on the development of Remicade and Glybera, the first gene therapy approved in the West. He ran VectorY as chief executive from November 2022 until Scibetta's arrival.

The presence of Eli Lilly and MRL Ventures, the venture arm of Merck & Co, on the shareholder list gives the company ties to two large pharma groups active in neuroscience. Neither has announced a partnership with VectorY.

The investigational therapy has not been approved anywhere. With enrolment under way at several sites and the trial now three times its original size, the next marker for VectorY's backers is the first safety and biomarker data from PIONEER-ALS, and whether the antibody that neurons produce actually lowers the TDP-43 burden in people.

What did you think of this story?

Written by

Jascinta Clark

52 stories on European Startup Insider

Have a story like this? Pitch it to us.

We publish founder profiles, company news and practical guides from across Europe.

You’ve finished this story

Up next

Biograil closes €20m to take its swallowable injection capsule towards first human trials

The Danish biotech, which packs a drug-delivery device into a standard capsule, will use the money for safety studies and manufacturing set-up ahead of a bigger raise planned for 2027.